Related Experiment Video

Updated: Aug 15, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

mTOR inhibitors in hematologic malignancies

Janet E Dancey1

  • 1Investigational Drug Branch, Cancer Treatment Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Rockville, MD 20854, USA. danceyj@ctep.nci.nih.gov

Clinical Advances in Hematology & Oncology : H&O
|November 1, 2005
PubMed

Insights

Rapamycin derivatives show promise for treating hematologic malignancies by inhibiting mammalian target of rapamycin (mTOR), a key regulator of cell growth. Clinical trials are evaluating these agents for improved cancer therapy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Hematologic malignancies often develop resistance to chemotherapy.
  • Rapamycin, an immunosuppressant, and its derivatives (RAD001, CCI-779) are being investigated as cancer therapeutics.
  • Rapamycin targets the mammalian target of rapamycin (mTOR) pathway, crucial for cell growth regulation.

Purpose of the Study:

  • To review advances in understanding rapamycin's cell growth inhibition mechanisms.
  • To summarize clinical trial results for RAD001 and CCI-779 in cancer treatment.
  • To explore the rationale for using rapamycin derivatives in hematologic malignancies.

Main Methods:

  • Literature review of rapamycin's mechanism of action.
  • Analysis of clinical trial data for RAD001 and CCI-779.
  • Examination of preclinical and clinical studies on rapamycin derivatives in hematologic cancers.

Main Results:

  • Rapamycin inhibits mTOR, affecting mRNA translation and cell cycle progression (G1 to S phase).
  • RAD001 and CCI-779 are under clinical development as anti-cancer agents.
  • The mTOR pathway is a relevant target for overcoming chemoresistance in hematologic malignancies.

Conclusions:

  • Rapamycin derivatives offer a promising therapeutic strategy for hematologic malignancies.
  • Further investigation into mTOR inhibition is warranted for improving cancer treatment outcomes.
  • Understanding rapamycin's mechanism provides a basis for its application in oncology.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...